Clinical trials: Hyperglycaemia (Diabetic)
Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"
The study will determine whether the anti-CD3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes (T1D) in relatives determined to be at very high risk for developing the disease.
- Conditions
- Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk, Impaired Glucose Tolerance
- Trial name
- NCT01030861
- Testing
- Teplizumab
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 76 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetic Ketoacidosis, Type 1 Diabetes Mellitus
Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes
A frequent complication in the management of diabetic ketoacidosis (DKA) in children with type 1 diabetes is rebound hyperglycemia (blood glucose over 180 mg/dL) which increases the risk of re-developing DKA and can lengthen the…
- Trial name
- NCT03107208
- Testing
- Glargine, Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Diabetes Mellitus, Type 1
Effects of Micronutrient (Chromium) Supplementation on Diabetes
6-8% of USA population has diabetes. Intensive blood glucose control dramatically reduces the devastating complications that result from poorly controlled diabetes.
- Trial name
- NCT01709123
- Testing
- chromium niacinate
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Louisiana State University Health Sciences Center Shreveport